|1.||Chen-Kiang, Selina: 5 articles (05/2015 - 08/2006)|
|2.||Di Liberto, Maurizio: 5 articles (05/2015 - 08/2006)|
|3.||Huang, Xiangao: 4 articles (05/2015 - 07/2008)|
|4.||Toogood, Peter L: 4 articles (07/2008 - 11/2004)|
|5.||Ely, Scott: 3 articles (09/2014 - 08/2006)|
|6.||Martin, Peter: 3 articles (09/2014 - 05/2012)|
|7.||Leonard, John P: 3 articles (09/2014 - 05/2012)|
|8.||Randolph, Sophia: 3 articles (07/2014 - 03/2011)|
|9.||Ginther, Charles: 3 articles (08/2013 - 01/2009)|
|10.||Slamon, Dennis J: 3 articles (08/2013 - 01/2009)|
01/01/2009 - "These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991"
01/01/2015 - "PD0332991 treatment (150mg/kg daily), reduced tumor size and tumor number. "
01/01/2015 - "CDK4/6 inhibitor PD-0332991 was sensitive in cancer cells with CDKN2A mutation, revealed in GDSC database. "
06/15/2013 - "Accordingly, inhibition of PI3Kδ induces apoptosis of primary MCL tumor cells once they have ceased to cycle ex vivo, and this killing is enhanced by PD 0332991 inhibition of CDK4/CDK6. "
04/07/2005 - "On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer."
|2.||Glioblastoma (Glioblastoma Multiforme)
01/01/2015 - "Outcomes of these studies have been contrasting in terms of PD0332991 efficacy within the brain: more research is necessary to conclude whether CDK4/6 inhibitor can be beneficial in the treatment of glioblastoma. "
01/01/2015 - "Promising results in in vitro studies, where patient derived glioblastoma cell lines showed sensitivity to PD0332991, gave motive to start in vivo studies. "
01/01/2015 - "CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?"
07/01/2012 - "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells."
01/01/2015 - "Common alterations in the cyclin D1-cyclin-dependent kinase 4/6-retinoblastoma 1 pathway in glioblastoma make PD0332991 also an interesting drug for the treatment of glioblastoma. "
|4.||Sarcoma (Soft Tissue Sarcoma)
|5.||Breast Neoplasms (Breast Cancer)
03/01/2015 - "Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I activity, we performed a phase II, single-arm trial of palbociclib in advanced breast cancer. "
11/02/2010 - "A clinical presurgical study will be required to better understand how PD 0332991 affects signaling pathways and how the intratumoral concentration of PD 0332991 correlates with plasma PK parameters and molecular alterations in breast cancer tissues after PD 0332991 treatment. "
05/01/2015 - "Modulation of Brk in breast cancer cells modulates pY88 and increases resistance to the cdk4 inhibitor PD 0332991. "
03/01/2015 - "CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment."
01/01/2015 - "In human breast cancer cells, simultaneous knockdown of Rb and FZR1 synergistically bypasses cell division arrest induced by the CDK4/6-specific inhibitor PD-0332991. "
|2.||Cyclin-Dependent Kinase 4
|6.||Small Interfering RNA (siRNA)
|8.||Dihydrotachysterol (AT 10)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)